S&P 500   4,362.94 (-1.07%)
DOW   34,309.63 (-0.16%)
QQQ   346.37 (-1.96%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,362.94 (-1.07%)
DOW   34,309.63 (-0.16%)
QQQ   346.37 (-1.96%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,362.94 (-1.07%)
DOW   34,309.63 (-0.16%)
QQQ   346.37 (-1.96%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
S&P 500   4,362.94 (-1.07%)
DOW   34,309.63 (-0.16%)
QQQ   346.37 (-1.96%)
AAPL   160.67 (-0.59%)
MSFT   290.75 (-1.90%)
FB   302.03 (-2.16%)
GOOGL   2,556.40 (-2.28%)
AMZN   2,800.97 (-3.11%)
TSLA   928.67 (-0.14%)
NVDA   224.71 (-3.86%)
BABA   119.90 (-0.39%)
NIO   23.99 (-3.54%)
AMD   111.87 (-4.00%)
CGC   7.39 (-0.14%)
MU   81.13 (-2.19%)
GE   91.03 (-6.07%)
T   26.44 (+0.38%)
F   20.08 (-1.52%)
DIS   136.45 (-0.73%)
AMC   16.13 (-3.06%)
PFE   52.39 (+1.65%)
ACB   4.22 (-2.31%)
BA   203.75 (-0.22%)
NASDAQ:MBIO

Mustang Bio Stock Forecast, Price & News

$1.22
-0.09 (-6.54%)
(As of 01/25/2022 03:39 PM ET)
Add
Compare
Today's Range
$1.16
▼
$1.25
50-Day Range
$1.30
▼
$2.32
52-Week Range
$1.15
▼
$5.22
Volume
28,217 shs
Average Volume
932,385 shs
Market Capitalization
$113.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.55
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.


Mustang Bio logo

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Headlines

Mustang Bio down 9% following IND application hold, continuing rough year
January 25, 2022 |  seekingalpha.com
FDA Holds Mustang Bio's Gene Therapy IND For Compromised Immune System Disorder
January 25, 2022 |  finance.yahoo.com
FDA puts on hold Mustang Bio's IND application for MB-207 in rare genetic disorder
January 25, 2022 |  seekingalpha.com
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
January 24, 2022 |  finance.yahoo.com
Mustang Bio (NASDAQ:MBIO) Price Target Cut to $6.00 by Analysts at B. Riley
January 24, 2022 |  americanbankingnews.com
Mustang Bio (NASDAQ:MBIO) Given New $6.00 Price Target at B. Riley
January 24, 2022 |  americanbankingnews.com
Mustang Bio, Inc. Common Stock (MBIO)
January 20, 2022 |  nasdaq.com
Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
January 5, 2022 |  finance.yahoo.com
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
December 9, 2021 |  finance.yahoo.com
Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
December 6, 2021 |  finance.yahoo.com
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 12, 2021 |  finance.yahoo.com
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
November 4, 2021 |  finance.yahoo.com
Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development
November 1, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBIO
Previous Symbol
CUSIP
N/A
CIK
1680048
Web
www.mustangbio.com
Phone
(781) 652-4500
Fax
N/A
Employees
62
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.35 per share
Price / Book
0.90

Profitability

EPS (Most Recent Fiscal Year)
($0.86)
Net Income
$-60.01 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-54.74%
Return on Assets
-50.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.66
Quick Ratio
11.66

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
93,428,000
Free Float
91,466,000
Market Cap
$113.52 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/25/2022
Next Earnings (Estimated)
3/23/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.04 out of 5 stars

Medical Sector

578th out of 621 stocks

Pharmaceutical Preparations Industry

273rd out of 298 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

Is Mustang Bio a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Mustang Bio stock.
View analyst ratings for Mustang Bio or view top-rated stocks.

How has Mustang Bio's stock price been impacted by COVID-19 (Coronavirus)?

Mustang Bio's stock was trading at $2.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MBIO shares have decreased by 48.3% and is now trading at $1.2150.
View which stocks have been most impacted by COVID-19.

When is Mustang Bio's next earnings date?

Mustang Bio is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022.
View our earnings forecast for Mustang Bio.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01.
View Mustang Bio's earnings history.

What price target have analysts set for MBIO?

4 Wall Street analysts have issued 1 year target prices for Mustang Bio's stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Mustang Bio's share price to reach $8.00 in the next year. This suggests a possible upside of 558.4% from the stock's current price.
View analysts' price targets for Mustang Bio or view top-rated stocks among Wall Street analysts.

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the following people:

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu Biopharma (AYTU) and (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $1.22.

How much money does Mustang Bio make?

Mustang Bio has a market capitalization of $113.52 million. The company earns $-60.01 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Mustang Bio have?

Mustang Bio employs 62 workers across the globe.

What is Mustang Bio's official website?

The official website for Mustang Bio is www.mustangbio.com.

Where are Mustang Bio's headquarters?

Mustang Bio is headquartered at 377 PLANTATION STREET, WORCESTER MA, 01605.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company can be reached via phone at (781) 652-4500 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.